Jason Lecocq
Overview
Explore the profile of Jason Lecocq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haselkorn T, Mink D, Kianifard F, Ortiz B, Paknis B, Lecocq J, et al.
Ann Allergy Asthma Immunol
. 2021 Aug;
127(5):593-595.
PMID: 34391902
No abstract available.
2.
Sullivan P, Ghushchyan V, Skoner D, Lecocq J, Park S, Zeiger R
J Allergy Clin Immunol Pract
. 2020 Dec;
9(4):1541-1551.e9.
PMID: 33290914
Background: Limited comparative data are available on the impact of systemic corticosteroid (SCS) use in children and adolescents. Objective: To determine if asthmatic children and adolescents treated with SCS have...
3.
Ference E, Reddy S, Tieu R, Gokhale S, Park S, Lecocq J
OTO Open
. 2020 Sep;
4(3):2473974X20950727.
PMID: 32944677
Objective: To investigate the clinical and health care burden of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) in the United States. Study Design: Retrospective, cross-sectional design with analyses of patient...
4.
Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al.
Clin Ther
. 2019 Sep;
41(10):1956-1971.
PMID: 31563391
Purpose: Biomarkers, including blood eosinophils (EoS) and fractional exhaled nitric oxide (FeNO), may affect omalizumab outcomes in allergic asthma, but evidence in the literature remains mixed. This study assessed omalizumab...
5.
Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al.
Allergy Asthma Proc
. 2019 Jul;
40(5):321-328.
PMID: 31345280
Although clinical trials documented omalizumab's efficacy in U.S. patients with chronic idiopathic urticaria (CIU), the real-world evidence on its long-term effectiveness is lacking. To assess omalizumab use and the long-term...
6.
Sullivan P, Kavati A, Ghushchyan V, Lanz M, Ortiz B, Maselli D, et al.
J Asthma
. 2019 Jul;
57(11):1263-1272.
PMID: 31311356
To estimate the health-related quality of life (HRQoL) and health utilities among asthma patients with and without comorbid allergies in a managed care population. This was a retrospective analysis of...
7.
Sullivan P, Lanz M, Ghushchyan V, Kavati A, Lecocq J, Ortiz B, et al.
J Asthma
. 2019 Jul;
57(9):959-967.
PMID: 31264894
To compare healthcare resource utilization (HCRU), healthcare expenditures, and work productivity and activity impairment within a general asthma population with persistent asthma and evidence of allergy (PA-EA) and persistent asthma...
8.
Sullivan P, Lanz M, Ghushchyan V, Kavati A, Lecocq J, Ortiz B, et al.
Allergy Asthma Proc
. 2019 May;
40(4):221-229.
PMID: 31053178
Approximately two-thirds of people with asthma have some evidence of allergy; their condition differs from nonallergic asthma in terms of predominant symptoms and clinical outcomes. To compare asthma control and...